Show simple item record

dc.creatorMeng, Fanping
dc.creatorXu, Ruonan
dc.creatorWang, Siyu
dc.creatorXu, Zhe
dc.creatorZhang, Chao
dc.creatorLi, Yuanyuan
dc.creatorYang, Tao
dc.creatorShi, Lei
dc.creatorFu, Junliang
dc.creatorJiang, Tianjun
dc.creatorHuang, Lei
dc.creatorZhao, Peng
dc.creatorYuan, Xin
dc.creatorFan, Xing
dc.creatorZhang, Ji-Yuan
dc.creatorSong, Jinwen
dc.creatorZhang, Dawei
dc.creatorJiao, Yanmei
dc.creatorLiu, Limin
dc.creatorZhou, Chunbao
dc.creatorMaeurer, Markus
dc.creatorZumla, Alimuddin
dc.creatorShi, Ming
dc.creatorWang, Fu-Sheng
dc.date.accessioned2020-09-30T20:56:17Z
dc.date.available2020-09-30T20:56:17Z
dc.date.created2020
dc.identifier.issn2059-3635spa
dc.identifier.otherhttps://doi.org/10.1038/s41392-020-00286-5spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/14046
dc.description.abstractNo effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors require clinical evaluation. We performed a parallel assigned controlled, non-randomized, phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease. The study enrolled 18 hospitalized patients with COVID-19 (n = 9 for each group). The treatment group received three cycles of intravenous infusion of UC-MSCs (3 × 107 cells per infusion) on days 0, 3, and 6. Both groups received standard COVID-treatment regimens. Adverse events, duration of clinical symptoms, laboratory parameters, length of hospitalization, serial chest computed tomography (CT) images, the PaO2/FiO2 ratio, dynamics of cytokines, and IgG and IgM anti-SARS-CoV-2 antibodies were analyzed. No serious UC-MSCs infusion-associated adverse events were observed. Two patients receiving UC-MSCs developed transient facial flushing and fever, and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion. Mechanical ventilation was required in one patient in the treatment group compared with four in the control group. All patients recovered and were discharged. Our data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated. Phase 2/3 randomized, controlled, double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve long-term treatment outcomes in patients with serious COVID-19.spa
dc.format.extent7 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherSignal Transduction and Targeted Therapyspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectHuman umbilical cord-derivedspa
dc.subjectStem cell therapyspa
dc.subjectCOVID-19spa
dc.subjectPatientsspa
dc.titleHuman umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trialspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.subject.lembClinical trialspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1038/s41392-020-00286-5spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record